-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, F2Cd1tzVfpYLutM4jwZtqbDoLmuKr7RWXNtxi+ppFx/Azc5ZfUNBgu3j/uMvybTv edN39OL/fZjELAjdau/o9A== 0000950134-06-005486.txt : 20060320 0000950134-06-005486.hdr.sgml : 20060320 20060320073027 ACCESSION NUMBER: 0000950134-06-005486 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20060320 ITEM INFORMATION: Other Events FILED AS OF DATE: 20060320 DATE AS OF CHANGE: 20060320 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ENCYSIVE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000887023 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133532643 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-20117 FILM NUMBER: 06697427 BUSINESS ADDRESS: STREET 1: 4848 LOOP CENTRAL DRIVE STREET 2: SUITE 700 CITY: HOUSTON STATE: TX ZIP: 77081 BUSINESS PHONE: 7137968822 MAIL ADDRESS: STREET 1: 4848 LOOP CENTRAL DRIVE STREET 2: SUITE 700 CITY: HOUSTON STATE: TX ZIP: 77081 FORMER COMPANY: FORMER CONFORMED NAME: TEXAS BIOTECHNOLOGY CORP /DE/ DATE OF NAME CHANGE: 19930328 8-K 1 h34227e8vk.htm ENCYSIVE PHARMACEUTICALS INC. e8vk
Table of Contents

 
 
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 20, 2006
Encysive Pharmaceuticals Inc.
(Exact name of registrant as specified in its charter)
         
Delaware   0-20117   13-3532643
 
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)
     
4848 Loop Central Drive, Suite 700, Houston, Texas   77081
(Address of principal executive offices)   (Zip Code)
Registrant’s telephone number, including area code: 713-796-8822
Not Applicable
 
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

TABLE OF CONTENTS

Item 8.01 Other Events
SIGNATURES

Table of Contents

Item 8.01 Other Events.
     On March 20, 2006, Encysive Pharmaceuticals, Inc. (the “Company”) announced the appointment of Thierry A. Plouvier, M.D., age 48, as Vice President, European Operations, a new position within the Company. Dr. Plouvier will oversee operations in the European Union, including sales and marketing, and headquarters’ functions, in support of the anticipated European launch of sitaxsentan sodium (Thelin™) in 2006. He will report to George W. Cole, the Company’s Chief Operating Officer.
     Dr. Plouvier joins the Company from Organon SA, the French subsidiary of Dutch pharmaceutical company Organon, where he served as President and Chief Executive Officer from May 2005 to February 2006. Prior to this, he served as President and Managing Director of Chiesi SA from November 1999. Dr. Plouvier received a Doctor of Medicine degree from the University of Paris VII and an M.B.A. from Stanford Graduate School of Business.
[SIGNATURE PAGE FOLLOWS]

 

Table of Contents

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
 
  ENCYSIVE PHARMACEUTICALS INC.    
 
  (Registrant)    
 
        
Date: March 20, 2006
        
 
  /s/ Gordon H. Busenbark    
 
 
 
Gordon H. Busenbark 		   
 
  Chief Financial Officer    

 

-----END PRIVACY-ENHANCED MESSAGE-----